RedHill Biopharma annual return on equity
2016
2017
2018
2019
2020
2021
RedHill Biopharma Return on Equity (ROE) Growth & History (RDHL)
RedHill Biopharma's return on equity was −859.70% for fiscal 2021.
View full RedHill Biopharma company overviewRedHill Biopharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2021 | 2021-12-31 | −859.70% | −653.46 pp |
| 2020 | 2020-12-31 | −206.25% | −130.15 pp |
| 2019 | 2019-12-31 | −76.09% | +4.57 pp |
| 2018 | 2018-12-31 | −80.66% | +3.86 pp |
| 2017 | 2017-12-31 | −84.52% | −36.68 pp |
| 2016 | 2016-12-31 | −47.84% | — |
RedHill Biopharma quarterly return on equity
Q2.18
Q2.19
Q2.20
Q2.21
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2021 | 2021-06-30 | −134.06% | −100.13 pp |
| Q2 2020 | 2020-06-30 | −33.93% | −7.67 pp |
| Q2 2019 | 2019-06-30 | −26.26% | +5.08 pp |
| Q2 2018 | 2018-06-30 | −31.33% | — |
RedHill Biopharma return on equity trends
Over the last five fiscal years, RedHill Biopharma's return on equity decreased from −47.84% to −859.70%, a change of −811.86 percentage points. The latest reported quarter, Q2 2021, shows −134.06%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review RedHill Biopharma source filings ↗